Complete Summary

GUIDELINE TITLE

Rhabdomyolysis.

BIBLIOGRAPHIC SOURCE(S)


GUIDELINE STATUS

This is the current release of the guideline.

COMPLETE SUMMARY CONTENT

SCOPE

METHODOLOGY - including Rating Scheme and Cost Analysis
RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
CATEGORIES
IDENTIFYING INFORMATION AND AVAILABILITY
DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

Rhabdomyolysis

GUIDELINE CATEGORY

Diagnosis
Treatment

CLINICAL SPECIALTY

Emergency Medicine
Internal Medicine
Nephrology

INTENDED USERS
GUIDELINE OBJECTIVE(S)

Evidence-Based Medicine Guidelines collect, summarize, and update the core clinical knowledge essential in general practice. The guidelines also describe the scientific evidence underlying the given recommendations.

TARGET POPULATION

Patients having or suspected of having rhabdomyolysis

INTERVENTIONS AND PRACTICES CONSIDERED

Diagnosis

1. Evaluation of signs, symptoms, and history
2. Serum creatinine kinase (CK)
3. Other laboratory findings including calcium, potassium, phosphatase, and urine hemoglobin levels

Treatment

1. Admission to hospital
2. Correction of hypovolaemia and dehydration with physiologic saline
3. Forced alkaline diuresis
4. Dialysis, if indicated
5. Fasciotomy, if indicated

MAJOR OUTCOMES CONSIDERED

Not stated

METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources)
Hand-searches of Published Literature (Secondary Sources)
Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The evidence reviewed was collected from the Cochrane database of systematic reviews and the Database of Abstracts of Reviews of Effectiveness (DARE). In addition, the Cochrane Library and medical journals were searched specifically for original publications.
METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Levels of Evidence

A. Strong research-based evidence. Multiple relevant, high-quality scientific studies with homogenic results.
B. Moderate research-based evidence. At least one relevant, high-quality study or multiple adequate studies.
C. Limited research-based evidence. At least one adequate scientific study.
D. No research-based evidence. Expert panel evaluation of other information.

METHODS USED TO ANALYZE THE EVIDENCE

Systematic Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Not stated
MAJOR RECOMMENDATIONS

The levels of evidence [A-D] supporting the recommendations are defined at the end of the "Major Recommendations" field.

Aims

- Suspect rhabdomyolysis in patients with typical history (particularly those found unconscious or those who have suffered a crush injury), symptoms, and clinical findings.
- When suspicion arises, diagnosis is easy to verify (serum creatine kinase [CK]).

Definition

- Rhabdomyolysis refers to an injury of striated muscle. It may result in acute renal failure unless treatment is instigated early enough.

Aetiology

- The most common causative factor is lying unconscious on a hard surface either as a result of intoxication (alcohol or medication), or due to an illness. The long lasting pressure will cause muscle damage.
- Crush injury, excessive muscle strain (running, body building, etc.), and convulsions
- Alcohol and illegal drugs (heroin, cocaine)
- Medication (statins)
- Hyperthermia (malignant hyperthermia, neuroleptic malignant syndrome)
- Metabolic disorders (hyperosmolar coma, ketoacidosis, hypokalaemia, hypophosphataemia)
- Infections (pneumococcus, salmonella, legionella, influenza, cytomegalovirus)
- Myopathy (congenital muscle enzyme deficiency, alcohol)

When to Suspect?

- A typical history involves a patient
  - Who has been lying unconscious on a hard surface due to excess alcohol, medication, or another reason, or
  - With excessive muscle strain over the preceding hours or days
- Signs and symptoms:
  - The affected area (limbs, buttocks, back) is painful, swollen, or tender to touch.
  - The patient may be unconscious, confused, dehydrated, or febrile.
  - Paresis or sensory disturbance may be present in the limbs (increased compartment pressure).
  - Urine may be dark (myoglobin), or the patient may be oliguric or anuric.
- Urine strip test may be positive to haematuria (due to myoglobin), even when no red cells are seen in the sediment.
**Diagnosis**

- If rhabdomyolysis is suspected, measure serum creatine kinase.
- CK activity is often >10,000-100,000 U/L.
- In clinical practice, the measurement of other muscle enzymes is not needed.
- Other typical laboratory findings include:
  - Hypocalcaemia (calcium deposited in muscle tissue)
  - Hyperkalaemia
  - Hyperphosphataemia (renal failure and release from cells)
  - Urine hemoglobin (Hb) positive in approximately 50% of patients
  - Increased serum creatinine as renal failure develops
- Differential diagnosis: Local symptoms may resemble those of deep venous thrombosis.

**Treatment**

- The patient is usually admitted to hospital.
- In primary care the first aid consists of the correction of hypovolaemia and dehydration.
  - Start with physiological saline
    - 1,000 milliliters (mL) during the first hour
    - Followed by 400-500 mL/hour
  - The aim is to prevent the development of acute renal failure, caused by myoglobin which is being released from the muscles.
- In the hospital the follow-up treatment consists of the following:
  - Correction of dehydration to maintain diuresis. Forced alkaline diuresis should be used to prevent renal failure; aim to keep urine pH at 7.5.
    - Initially 1,000 mL of 0.9% sodium chloride (NaCl) over 1 hour
    - Followed by 0.3% sodium chloride with 5% glucose 400 mL/hour
  - Urine is alkalinized with a side infusion of 1.4% sodium bicarbonate (NaHCO3) administered 50-100 mL/hour, or 7.5% sodium bicarbonate administered 10-20 mL/hour.
  - Diuresis may be encouraged with 20-40 milligrams of intravenous furosemide.
  - Dialysis is indicated in renal failure if the patient is anuric and diuresis is not induced with rehydration.
    - Dialysis will have no effect on the renal state, but will keep the patient alive until renal function spontaneously returns. This may take several days, even weeks.
  - Fasciotomy is indicated if increased compartment pressure threatens to cause muscle necrosis or nerve damage.
  - Correction of symptomatic hypocalcaemia must be carried out cautiously, because hypercalcaemia often develops during recovery. Asymptomatic hypocalcaemia requires no treatment.

**Prognosis**

- Prognosis is good even in cases where renal failure has developed, since the failure is reversible.
  - If compartment syndrome is not treated early enough, residual nerve and muscle damage may persist.
Reference: (Better & Stein, 1990)

**Definitions**

**Levels of Evidence**

A. Strong research-based evidence. Multiple relevant, high-quality scientific studies with homogenic results.
B. Moderate research-based evidence. At least one relevant, high-quality study or multiple adequate studies.
C. Limited research-based evidence. At least one adequate scientific study.
D. No research-based evidence. Expert panel evaluation of other information.

**CLINICAL ALGORITHM(S)**

None provided

**EVIDENCE SUPPORTING THE RECOMMENDATIONS**

**REFERENCES SUPPORTING THE RECOMMENDATIONS**

References open in a new window

**TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS**

Concise summaries of scientific evidence attached to the individual guidelines are the unique feature of the Evidence-Based Medicine Guidelines. The evidence summaries allow the clinician to judge how well-founded the treatment recommendations are. The type of supporting evidence is identified and graded for select recommendations (see the "Major Recommendations" field).

**BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS**

**POTENTIAL BENEFITS**

- Accurate diagnosis and appropriate treatment of rhabdomyolysis
- The aim of treatment is to prevent the development of acute renal failure.

**POTENTIAL HARMs**

Not stated

**IMPLEMENTATION OF THE GUIDELINE**

**DESCRIPTION OF IMPLEMENTATION STRATEGY**

An implementation strategy was not provided.
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT

CATEGORIES

IOM CARE NEED

Getting Better

IOM DOMAIN

Effectiveness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)


ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2004 Jun 16

GUIDELINE DEVELOPER(S)

Finnish Medical Society Duodecim - Professional Association

SOURCE(S) OF FUNDING

Finnish Medical Society Duodecim

GUIDELINE COMMITTEE

Editorial Team of EBM Guidelines

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Primary Author: Heikki Saha

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS
This is the current release of the guideline.

GUIDELINE AVAILABILITY

This guideline is included in a CD-ROM titled "EBM Guidelines. Evidence-Based Medicine" available from Duodecim Medical Publications, Ltd, PO Box 713, 00101 Helsinki, Finland; e-mail: info@ebm-guidelines.com; Web site: www.ebm-guidelines.com.

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on August 31, 2005.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx.

NGC, AHRQ, and its contractor ECRI make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.
Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2007 National Guideline Clearinghouse

Date Modified: 3/19/2007